Role of Cholestyramine in Refractory Hyperthyroidism: A Case Report and Literature Review
- PMID: 26207323
- PMCID: PMC4517850
- DOI: 10.12659/AJCR.893821
Role of Cholestyramine in Refractory Hyperthyroidism: A Case Report and Literature Review
Abstract
Background: Hyperthyroidism is a common disease that usually responds to the conventional therapy of anti-thyroidal medications (methimazole or PTU) and beta-blocker. Refractory hyperthyroidism is a rare condition in which hyperthyroidism fails to respond to the above therapy. Cholestyramine has been shown to decrease thyroid hormone level when added to the ongoing anti-thyroidal medications.
Case report: A 52-year-old woman with past medical history of enlarging goiter presented with obstructive symptoms of worsening shortness of breath and snoring. Admission thyroid function test showed mild hyperthyroidism (suppressed TSH, slightly high FT4, and high normal FT3) that worsened after she received a CT scan with contrast and failed to respond to a 3-week course of high-dose dexamethasone, high-dose carbimazole, and up-titrated propranolol. Five days after cholestyramine was added, her FT4 decreased by 30% and normalized after 12 days. The patient underwent total thyroidectomy as definitive treatment for the hyperthyroidism and for the obstructive symptoms.
Conclusions: Cholestyramine is an effective additional treatment for hyperthyroidism and may be an effective treatment for refractory iodine-induced hyperthyroidism. The possibility of self-remission (natural course) is less likely given the dramatic and rapid response to cholestyramine.
Figures
Similar articles
-
The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.Clin Endocrinol (Oxf). 2005 May;62(5):521-4. doi: 10.1111/j.1365-2265.2005.02249.x. Clin Endocrinol (Oxf). 2005. PMID: 15853819 Clinical Trial.
-
Treatment of hyperthyroidism with a combination of methimazole and cholestyramine.J Clin Endocrinol Metab. 1996 Sep;81(9):3191-3. doi: 10.1210/jcem.81.9.8784067. J Clin Endocrinol Metab. 1996. PMID: 8784067 Clinical Trial.
-
Low doses of cholestyramine in the treatment of hyperthyroidism.Endocrine. 2008 Aug-Dec;34(1-3):52-5. doi: 10.1007/s12020-008-9107-5. Epub 2008 Oct 23. Endocrine. 2008. PMID: 18946743 Clinical Trial.
-
[Hyperthyroid rheumatism. Review of the literature and a case report].Presse Med. 2003 May 24;32(18):836-8. Presse Med. 2003. PMID: 12870386 Review. French.
-
Hyperthyroidism: diagnosis and treatment.Am Fam Physician. 2005 Aug 15;72(4):623-30. Am Fam Physician. 2005. PMID: 16127951 Review.
Cited by
-
Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study.J Transl Med. 2024 Mar 29;22(1):318. doi: 10.1186/s12967-024-05129-3. J Transl Med. 2024. PMID: 38553734 Free PMC article.
-
Cholestyramine as monotherapy for Graves' hyperthyroidism.Singapore Med J. 2016 Nov;57(11):644-645. doi: 10.11622/smedj.2016177. Singapore Med J. 2016. PMID: 27872940 Free PMC article. No abstract available.
-
Resistant type 2 amiodarone-induced thyrotoxicosis responsive to cholestyramine as an adjunctive therapy.Clin Med (Lond). 2021 Sep;21(5):e529-e530. doi: 10.7861/clinmed.2021-0482. Clin Med (Lond). 2021. PMID: 34507939 Free PMC article.
-
Nonthionamide Drugs for the Treatment of Hyperthyroidism: From Present to Future.Int J Endocrinol. 2018 Apr 22;2018:5794054. doi: 10.1155/2018/5794054. eCollection 2018. Int J Endocrinol. 2018. PMID: 29849619 Free PMC article. Review.
References
-
- Spitzweg C, Morris JC. Sodium iodide symporter (NIS) and thyroid. Hormons. 2002;1(1):22–34. - PubMed
-
- Lawrence JE, Lamm SH, Braverman LE. The use of perchlorate for the prevention of thyrotoxicosis in patients given iodine rich contrast agents. J Endocrinol Invest. 1999;22(5):405–7. - PubMed
-
- Gardner DF, Centor RM, Utiger RD. Effects of low dose iodide supplementation on thyroid function in normal men. Clin Endocrinol. 1988;28:283–88. - PubMed
-
- Azizi F, Hedayati M, Rahmani M, et al. Reappraisal of the risk of iodine-induced hyperthyroidism: an epidemiological population survey. J Endocrinol Invest. 2005;28(1):23–29. - PubMed
-
- Burman KD, Wartofsky L. Iodine effects on the thyroid gland: biochemical and clinical aspects. Rev Endocr Metab Disord. 2000;1(1–2):19–25. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous